Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.
Fuensanta Guerrero-Del-Cueto, Sara Lobato-Lopez, Diego Lozano-Duran, Blanca Sanchez-Duran, Lucia Ramirez-Martin, Begoña Esteban-San-Narciso, Sara Sosa-Hernandez, Laura Martin-Pedraz, David Moreno-Perez, Isabel Leiva-Gea, Esmeralda Nuñez-Cuadros
{"title":"Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.","authors":"Fuensanta Guerrero-Del-Cueto, Sara Lobato-Lopez, Diego Lozano-Duran, Blanca Sanchez-Duran, Lucia Ramirez-Martin, Begoña Esteban-San-Narciso, Sara Sosa-Hernandez, Laura Martin-Pedraz, David Moreno-Perez, Isabel Leiva-Gea, Esmeralda Nuñez-Cuadros","doi":"10.1002/ppul.71059","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluates nirsevimab's real-world effectiveness in preventing respiratory syncytial virus (RSV) bronchiolitis hospitalizations after its introduction in Andalusia's immunization schedule, compares clinical outcomes between immunized and non-immunized infants (2023-2024), and examines RSV seasonality pre- and post-COVID-19.</p><p><strong>Methods: </strong>Retrospective single-center case-control study conducted at a tertiary pediatric hospital (Malaga Regional University Hospital). Infants hospitalized for PCR-confirmed RSV bronchiolitis during the first season after nirsevimab introduction were matched with two controls born on the same day. Immunization status, demographic data, and clinical outcomes were analyzed. As a secondary analysis, clinical characteristics and adverse outcomes of immunized and non-immunized RSV bronchiolitis cases from the 2023-2024 season were compared with four previous periods: pre-pandemic decade (04/2010-03/2020), first pandemic season (04/2020-03/2021), second pandemic season (04/2021-03/2022) and third pandemic season (04/2022-03/2023).</p><p><strong>Results: </strong>Nirsevimab showed 91.5% effectiveness (95% CI: 71.8%-97.4%) in reducing RSV bronchiolitis hospitalizations, which decreased 72.4% from the pre-pandemic average and 82.4% from 04/2022-03/2023. Intensive-care-unit admissions were significantly higher in non-immunized infants (60.0% vs. 26.1%, p = 0.04), with no differences in bacterial superinfection, oxygen requirement and length-of-stay.</p><p><strong>Conclusions: </strong>Nirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study also highlights shifts in RSV seasonality trends influenced by the COVID-19 pandemic, highlighting the need for ongoing surveillance to adapt public health strategies.</p>","PeriodicalId":19932,"journal":{"name":"Pediatric Pulmonology","volume":"60 7","pages":"e71059"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261432/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ppul.71059","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study evaluates nirsevimab's real-world effectiveness in preventing respiratory syncytial virus (RSV) bronchiolitis hospitalizations after its introduction in Andalusia's immunization schedule, compares clinical outcomes between immunized and non-immunized infants (2023-2024), and examines RSV seasonality pre- and post-COVID-19.
Methods: Retrospective single-center case-control study conducted at a tertiary pediatric hospital (Malaga Regional University Hospital). Infants hospitalized for PCR-confirmed RSV bronchiolitis during the first season after nirsevimab introduction were matched with two controls born on the same day. Immunization status, demographic data, and clinical outcomes were analyzed. As a secondary analysis, clinical characteristics and adverse outcomes of immunized and non-immunized RSV bronchiolitis cases from the 2023-2024 season were compared with four previous periods: pre-pandemic decade (04/2010-03/2020), first pandemic season (04/2020-03/2021), second pandemic season (04/2021-03/2022) and third pandemic season (04/2022-03/2023).
Results: Nirsevimab showed 91.5% effectiveness (95% CI: 71.8%-97.4%) in reducing RSV bronchiolitis hospitalizations, which decreased 72.4% from the pre-pandemic average and 82.4% from 04/2022-03/2023. Intensive-care-unit admissions were significantly higher in non-immunized infants (60.0% vs. 26.1%, p = 0.04), with no differences in bacterial superinfection, oxygen requirement and length-of-stay.
Conclusions: Nirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study also highlights shifts in RSV seasonality trends influenced by the COVID-19 pandemic, highlighting the need for ongoing surveillance to adapt public health strategies.
期刊介绍：
Pediatric Pulmonology (PPUL) is the foremost global journal studying the respiratory system in disease and in health as it develops from intrauterine life though adolescence to adulthood. Combining explicit and informative analysis of clinical as well as basic scientific research, PPUL provides a look at the many facets of respiratory system disorders in infants and children, ranging from pathological anatomy, developmental issues, and pathophysiology to infectious disease, asthma, cystic fibrosis, and airborne toxins. Focused attention is given to the reporting of diagnostic and therapeutic methods for neonates, preschool children, and adolescents, the enduring effects of childhood respiratory diseases, and newly described infectious diseases.
PPUL concentrates on subject matters of crucial interest to specialists preparing for the Pediatric Subspecialty Examinations in the United States and other countries. With its attentive coverage and extensive clinical data, this journal is a principle source for pediatricians in practice and in training and a must have for all pediatric pulmonologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
